Some of the TRANSBIG publications:
- Clinical application of the 70-gene profile (Mammaprint™): The MINDACT trial. Journal of Clinical Oncology 26(5): 729–735, 2008.
- The MINDACT trial: the first prospective clinical validation of a genomic tool. Molecular Oncology 1(3), 246-251, 2007.
- Robust interlaboratory reproducibility of gene expression signature measurement consistent with the needs of a new generation of diagnostic tool. BMC Genomics, 8: 148, 2007.
- Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clinical Cancer Research - June 2007.
- Individualization of therapy using Mammaprint®?: from development to the MINDACT trial. Cancer Genomics and Proteomics, 4: 147-156, July 2007.
- Multi-centre independent validation of a 70-gene prognostic signature for women with node negative breast cancer, Journal of the National Cancer Institute - September 2006.
- Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node negative Disease May Avoid Chemotherapy Trial) Nature Clinical Practice Oncology - October 2006.
- Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Breast Cancer Research and Treatment - 2004.
- Gene expression profiling predicts clinical outcome of breast cancer. Nature Clinical Practice Oncology , 415: 530-536, 2002.
- A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medecine - 347: 1999-2009, 2002.
To find out about TRANSBIG and MINDACT in the news click here.